PF-Atlas › Clinical Trials › NCT05817240
A Drug-Drug Interaction Study of ENV-101 on Nintedanib Pharmacokinetics in Healthy Subjects
taladegib · Phase 1
Registry ID
NCT05817240
Phase
Phase 1
Status
Completed
Drug / intervention
taladegib
Sponsor
Endeavor Biomedicines, Inc.
Start
2023-05-03
Enrollment
21
Locations
1
About this trial
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05817240 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.